Nanobiotix (NANO) | News Based Sentiment Analysis

• On September 2, 2025, Nanobiotix announced that CEO Laurent Levy and CFO Bart van Rhijn would participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 9, 2025. This proactive investor relations effort aims to increase the company’s visibility and provide a direct communication channel with investors and analysts, signaling a commitment to transparency.
• Nanobiotix is expected to report its next earnings on September 17, 2025, with the current EPS estimate at -$0.35. While currently unprofitable, analysts forecast earnings to grow by 62.5% and revenue by 40.9% per annum, with EPS growth projected at 74.6% per annum, suggesting potential for future profitability despite short-term losses.
• Following the September 2, 2025 announcement of the H.C. Wainwright conference participation, an analyst maintained a "Strong Buy" rating for Nanobiotix on September 10, 2025, but lowered the 12-month price target to 8.00, a -14.44% decrease from the current stock price of 9.97. This suggests continued confidence in the company’s long-term potential, tempered by short-term market considerations.
• As of July 31, 2025, Nanobiotix reported 48,236,671 shares outstanding, with 50,340,736 total theoretical voting rights and 50,318,618 total exercisable voting rights, as released on August 27, 2025. This detailed information on the company’s capital structure provides clarity for investors regarding ownership and voting power.
• The September 9, 2025, presentation at the H.C. Wainwright conference, starting at 9:00 AM EDT, builds on the initial announcement made earlier in the month on September 2, 2025. This continued engagement suggests Nanobiotix is actively preparing for potential fundraising or partnership opportunities.

The Investment Story: September was a month of active investor engagement for Nanobiotix, balancing near-term unprofitability with optimistic long-term growth forecasts and maintaining transparency regarding its capital structure. The company is clearly focused on communicating its vision to the investment community.

What It Means for Investors: Despite the expected loss of $0.35 per share on September 17th, the projected growth rates suggest Nanobiotix could become a profitable company in the coming years. The lowered price target, while a concern, is coupled with a “Strong Buy” rating, indicating a complex but potentially rewarding investment opportunity.

Looking Ahead: Investors should closely monitor the September 17th earnings report and the details shared during the September 9th fireside chat for further insights into the company’s progress and future plans. Tracking investor reaction to these events will be crucial.

The Bottom Line: Nanobiotix is a high-growth, but currently unprofitable, company actively working to build investor confidence. This month’s developments highlight a proactive approach to communication and a clear focus on long-term value creation, making it a potentially attractive, albeit risky, investment for those seeking exposure to innovative nanomedicine.